Browse our 650+ Publications​

Latest Publications

Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer

Jhawar SR, et al.
Journal for ImmunoTherapy of Cancer
August 2023
Authors and Affiliates
Sachin R Jhawar 1, Shang-Jui Wang 1, Aditya Thandoni 2, Praveen K Bommareddy 3, Jenna H Newman 3, Amanda L Marzo 4, Timothy M Kuzel 4, Vineet Gupta 4, Jochen Reiser 4, Preston Daniels 4, Devora Schiff 3, Darrion Mitchell 1, Nicole R LeBoeuf 5,6, Christopher Simmons 7, Sharad Goyal 8, Ahmed Lasfar 3,9, Jose A Guevara-Patino 10, Bruce G Haffty 3, Howard L Kaufman 11, Ann W Silk 12,7, Andrew Zloza 13; 1 Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. 2 Department of Orthopedic Surgery, Allegheny Health Network, Pittsburgh, Pennsylvania, USA. 3 Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA. 4 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA. 5 Harvard Medical School, Boston, Massachusetts, USA. 6 Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA. 7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 8 Department of Radiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA. 9 Department of Pharmacology and Toxicology, Ernest School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA. 10 Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA. 11 Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. 12 Harvard Medical School, Boston, Massachusetts, USA andrewzloza@gmail.com ann_silk@dfci.harvard.edu. 13 Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA andrewzloza@gmail.com ann_silk@dfci.harvard.edu.

Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy

Dunlap GS, et al.
Nature Communications
August 2023
Authors and Affiliates
Garrett S Dunlap 1,2, Daniel DiToro 2,3, Joel Henderson 4, Sujal I Shah 2,3, Mike Manos 5, Mariano Severgnini 5, Astrid Weins 2,3, Indira Guleria 2,3, Patrick A Ott 2,5,6,7,8, Naoka Murakami # 9,10, Deepak A Rao # 11,12; 1 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. 2 Harvard Medical School, Boston, MA, USA. 3 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 4 Department of Pathology, Boston Medical Center and Boston University, Boston, MA, USA. 5 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 7 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 8 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 9 Harvard Medical School, Boston, MA, USA. nmurakami1@bwh.harvard.edu. 10 Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA. nmurakami1@bwh.harvard.edu. 11 Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, USA. darao@bwh.harvard.edu. 12 Harvard Medical School, Boston, MA, USA. darao@bwh.harvard.edu.

Intratumoral IFN-γ or topical TLR7 agonist promotes infiltration of melanoma metastases by T lymphocytes expanded in the blood after cancer vaccine

Tran CA, et al.
Journal of immunoTherapy of Cancer
August 2023
Authors and Affiliates
Christine A Tran 1, Kevin T Lynch 1, Max O Meneveau 1, Priya Katyal 2, Walter C Olson 1, Craig L Slingluff Jr 3,4; 1 Department of Surgery, University of Virginia Health, Charlottesville, Virginia, USA. 2 University of Virginia College and Graduate School of Arts and Sciences, Charlottesville, Virginia, USA. 3 Department of Surgery, University of Virginia Health, Charlottesville, Virginia, USA cls8h@virginia.edu. 4 Beirne Carter Center for Immunology Research, University of Virginia, Charlottesville, Virginia, USA.

Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells

Malle L, et al.
Nature
August 2023
Authors and Affiliates
Louise Malle 1,2,3,4,5, Roosheel S Patel 1,2,3,4,5, Marta Martin-Fernandez 1,2,3,4,5, O Jay Stewart 1,2,3,4,5, Quentin Philippot 6,7, Sofija Buta 1,2,3,4,5, Ashley Richardson 1,2,3,4,5, Vanessa Barcessat 4, Justin Taft 1,2,3,4,5, Paul Bastard 6,7,8,9, Julie Samuels 3, Clotilde Mircher 10, Anne-Sophie Rebillat 10, Louise Maillebouis 10, Marie Vilaire-Meunier 10, Kevin Tuballes 4, Brad R Rosenberg 5, Rebecca Trachtman 2,3, Jean-Laurent Casanova 6,7,8,11,12, Luigi D Notarangelo 13, Sacha Gnjatic 4, Douglas Bush 2, Dusan Bogunovic 14,15,16,17,18; 1 Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2 Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3 Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 6 Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. 7 University of Paris, Imagine Institute, Paris, France. 8 St Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA. 9 Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France. 10 Institut Jérôme Lejeune, Paris, France. 11 Department of Pediatrics, Necker Hospital for Sick Children, Paris, France. 12 Howard Hughes Medical Institute, New York, NY, USA. 13 Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 14 Center for Inborn Errors of Immunity, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dusan.Bogunovic@mssm.edu. 15 Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dusan.Bogunovic@mssm.edu. 16 Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dusan.Bogunovic@mssm.edu. 17 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dusan.Bogunovic@mssm.edu. 18 Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Dusan.Bogunovic@mssm.edu.

Immunosurveillance shapes the emergence of neo-epitope landscapes of sarcomas, revealing prime targets for immunotherapy

Osei-Hwedieh DO, et al.
JCI Insight
August 2023
Authors and Affiliates
David O Osei-Hwedieh 1, Abigail L Sedlacek 1, Luis Mena Hernandez 1, Archibald Agyekum Yamoah 2, Swati G Iyer 1, Kurt R Weiss 3, Robert J Binder 1; 1 Department of Immunology and. 2 Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3 Department of Orthopaedic Surgery, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.

COVID-19 vaccination produces exercise-responsive SARS-CoV-2-specific T-cells regardless of infection history

Smith KA, et al.
Journal of Health and Sports Science
August 2023
Authors and Affiliates
Kyle A Smith 1, Tiffany M Zúñiga 1, Forrest L Baker 2, Helena Batatinha 1, Charles R Pedlar 3, Shane C Burgess 4, Michael P Gustafson 5, Emmanuel Katsanis 6, Richard J Simpson 7; 1 School of Nutritional Sciences and Wellness, The University of Arizona, Tucson, AZ 85721, USA. 2 School of Nutritional Sciences and Wellness, The University of Arizona, Tucson, AZ 85721, USA; Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, USA. 3 Faculty of Sport, Allied Health and Performance Science, St. Mary's University, Twickenham TW1 4SX, UK; Institute of Sport Exercise and Health, University College London, London WC1E 7HU, UK. 4 Department of Animal and Comparative Biomedical Sciences, The University of Arizona, Tucson, AZ 85721, USA; The University of Arizona Cancer Center, The University of Arizona, Tucson, AZ 85719, USA. 5 Laboratory Medicine and Pathology, Mayo Clinic Arizona, Phoenix, AZ 85054, USA. 6 Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, USA; The University of Arizona Cancer Center, The University of Arizona, Tucson, AZ 85719, USA; Department of Immunobiology, The University of Arizona, Tucson, AZ 85724, USA; Department of Medicine, The University of Arizona, Tucson, AZ 85724, USA; Department of Pathology, The University of Arizona, Tucson, AZ 85724, USA. 7 School of Nutritional Sciences and Wellness, The University of Arizona, Tucson, AZ 85721, USA; Department of Pediatrics, The University of Arizona, Tucson, AZ 85724, USA; Department of Immunobiology, The University of Arizona, Tucson, AZ 85724, USA; Department of Medicine, The University of Arizona, Tucson, AZ 85724, USA. Electronic address: rjsimpson@arizona.edu.

A novel statistical method for decontaminating T-cell receptor sequencing data

Li R, et al.
Briefings in Bioinformatics
August 2023
Authors and Affiliates
Ruoxing Li 1,2, Mehmet Altan 3, Alexandre Reuben 3, Ruitao Lin 2, John V Heymach 3, Hai Tran 3, Runzhe Chen 3, Latasha Little 4, Shawna Hubert 3, Jianjun Zhang 3, Ziyi Li 2; 1 Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, 77030, Texas, Houston, USA. 2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 77030, Texas, Houston, USA. 3 Department of Thoracic-Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030, Texas, Houston, USA. 4 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 77030, Texas, Houston, USA.

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

Cascini C, et al.
Journal of Experimental Medicine
August 2023
Authors and Affiliates
Caterina Cascini 1, Chiara Ratti 1, Laura Botti 1, Beatrice Parma 1, Valeria Cancila 2, Adriana Salvaggio 1, Cristina Meazza 3, Claudio Tripodo 2 4, Mario P Colombo 1, Claudia Chiodoni 5; 1 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. 2 Department of Health Science, Tumor Immunology Unit, University of Palermo School of Medicine, Palermo, Italy. 3 Pediatric Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. 4 IFOM, FIRC Institute of Molecular Oncology, Milan, Italy. 5 Department of Experimental Oncology, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via Amadeo 42, 20133, Milan, Italy. claudia.chiodoni@istitutotumori.mi.it.

A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Page DB, et al.
NPJ Breast Cancer
August 2023
Authors and Affiliates
David B Page 1, Joanna Pucilowska 2, Brie Chun 2, Isaac Kim 2, Katherine Sanchez 2, Nicole Moxon 2, Staci Mellinger 2, Yaping Wu 2, Yoshinobu Koguchi 2, Valerie Conrad 2, William L Redmond 2, Maritza Martel 2, Zhaoyu Sun 2, Mary B Campbell 2, Alison Conlin 2, Anupama Acheson 2, Reva Basho 3,4, Philomena McAndrew 3, Mary El-Masry 3, Dorothy Park 3, Laura Bennetts 2, Robert S Seitz 5, Tyler J Nielsen 5, Kimberly McGregor 5, Venkatesh Rajamanickam 2, Brady Bernard 2, Walter J Urba 2, Heather L McArthur 3,6; 1 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. david.page2@providence.org. 2 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA. 3 Cedars Sinai Medical Center, Los Angeles, CA, USA. 4 Ellison Institute for Transformative Medicine, Los Angeles, CA, USA. 5 Oncocyte Corporation, Irving, CA, USA. 6 UT Southwestern Medical Center, Dallas, TX, USA.
Previous Next